RCT: Remdesivir does not improve outcomes in patients admitted to hospital with COVID-19.

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial – The Lancet Infectious Diseases

Invited commentary: Remdesivir, on the road to DisCoVeRy – The Lancet Infectious Diseases

Related:

Systematic Review: “Remdesivir probably has little or no effect on all‐cause mortality at up to 28 days in hospitalized adults with SARS‐CoV‐2 infection. We are uncertain about the effects of remdesivir on clinical improvement and worsening”.

WHO Solidarity Trial: Remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19